Jim Cramer: Buy Starbucks as shares give up their post-earnings gains

Stocks gained ahead of the Federal Reserve's policy announcement, with market participants focused on whether the central bank will signal a September rate cut amidst conflicting economic data. Separately, Starbucks shares declined despite initial premarket gains post-earnings, which Jim Cramer characterized as a buying opportunity due to high conviction in the CEO's turnaround plan. Eli Lilly shares rose over 1% following a positive Citigroup note, partially recovering from a prior sell-off, with long-term investor confidence supported by its pipeline obesity pill.

Analysis

The market is positioned ahead of a key Federal Reserve policy announcement, with investors focused on forward guidance for a potential September rate cut rather than any immediate action. The Fed's decision-making is complicated by conflicting economic signals, specifically a stronger-than-expected July ADP private payroll report contrasting with weaker June pending home sales. This divergence is also seen at a sector level, with commentary suggesting a 'hobbled' consumer dynamic while industrials, exemplified by Vertiv, are performing well. On a single-stock basis, Starbucks (SBUX) presents a notable situation where its shares reversed premarket gains of over 5% to trade lower post-earnings; this is viewed as a compelling entry point based on high conviction in the CEO's turnaround strategy. In the pharmaceutical sector, Eli Lilly (LLY) shares recovered over 1% following a positive Citigroup note, partially offsetting a prior sell-off linked to a competitor's drug safety warnings. While near-term risk is being managed ahead of its own earnings, the long-term bullish case for Lilly is reportedly intact, centered on its pipeline obesity pill anticipated for a 2026 launch.

Key Decisions for Investors

• Investors should closely monitor the Federal Reserve's post-meeting statement for any signals regarding a potential September rate cut, as conflicting economic data creates policy uncertainty.
• The post-earnings pullback in Starbucks (SBUX) may present a tactical buying opportunity for investors with high conviction in the ongoing CEO-led turnaround plan.
• For Eli Lilly (LLY), weigh the near-term volatility from its upcoming earnings and competitive news against its significant long-term growth catalyst, the oral obesity pill expected in 2026.
• Evaluate portfolio exposure based on the observed sector divergence, recognizing the described weakness in consumer-facing industries versus strength in select industrials.